{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0"}]}],"title":"More satisfied with atezolizumab SC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0"}]}],"title":"Equally satisfied with both formulations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0"}]}],"title":"More satisfied with atezolizumab IV"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"The HCP SC versus IV Perspective Questionnaire consisted of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as an IV infusion and as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 4 is being reported here: Question 4: Overall, were you more satisfied with atezolizumab SC or atezolizumab IV? The responses included: More satisfied with atezolizumab SC; Equally satisfied with both formulations; More satisfied with atezolizumab IV. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2).","groups":[{"description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, or atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the IV or SC formulations completed the HCP SC versus IV Perspective Questionnaire.","id":"OG000","title":"Part 2: Atezolizumab IV/Atezolizumab SC"}],"paramType":"NUMBER","populationDescription":"Overall number analyzed included HCPs who completed Question 4 of the questionnaire.","reportingStatus":"POSTED","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months)","title":"Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Versus IV Perspective Questionnaire","type":"SECONDARY","unitOfMeasure":"percentage of HCPs"}